Peter Park

Peter Park, PhD

Professor of Biomedical Informatics
Director, Bioinformatics and Integrative Genomics (BIG) PhD Track

10 Shattuck Street, Boston, MA 02115

Dr. Park is a Professor of Biomedical Informatics at Harvard Medical School and the director of its Bioinformatics and Integrative Genomics PhD program. His research group specializes in computational and statistical analysis of large-scale DNA sequencing data to understand genetic and epigenetic mechanisms related to disease processes. Originally trained in applied mathematics (B.A., Harvard; Ph.D., Caltech), he was introduced to molecular biology and genetics during his postdoctoral studies in biostatistics. His laboratory has developed several algorithms for identifying and interpreting genomic alterations in the human genome, especially those from cancer patients. His group has made major contributions to many consortium projects such as The Cancer Genome Atlas (TCGA), Encyclopedia of DNA Elements (ENCODE), and Brain Somatic Mosaicism Network, and 4D Nucleome, and Somatic Mosaicism across Human Tissues (SMaHT). His work has been funded by the National Institutes of Health, Cancer Research UK Grand Challenges, The Mark Foundation for Cancer Research, Simons Foundation, Chan Zucherberg Initiative, Blavatnik Therapeutics Challenge, the HMS Quadrangle Fund for Advancing and Seeding Translational Research (Q-FASTR), and others.


DBMI Research Areas
DBMI Courses
Contribution of de novo retroelements to birth defects and childhood cancers.
Authors: Chu C, Ljungström V, Tran A, Jin H, Park PJ.
medRxiv
View full abstract on Pubmed
Contrasting somatic mutation patterns in aging human neurons and oligodendrocytes.
Authors: Ganz J, Luquette LJ, Bizzotto S, Miller MB, Zhou Z, Bohrson CL, Jin H, Tran AV, Viswanadham VV, McDonough G, Brown K, Chahine Y, Chhouk B, Galor A, Park PJ, Walsh CA.
Cell
View full abstract on Pubmed
A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
Authors: Boiarsky D, Gulhan DC, Savignano H, Lakshminarayanan G, McClure HM, Silver R, Hirsch MS, Sholl LM, Choudhury AD, Ananda G, Park PJ, Tewari AK, Berchuck JE.
Clin Genitourin Cancer
View full abstract on Pubmed
Epigenetic profiling reveals key genes and cis-regulatory networks specific to human parathyroids.
Authors: Jung YL, Zhao W, Li I, Jain D, Epstein CB, Bernstein BE, Parangi S, Sherwood R, Robinson-Cohen C, Hsu YH, Park PJ, Mannstadt M.
Nat Commun
View full abstract on Pubmed
Accurate and sensitive mutational signature analysis with MuSiCal.
Authors: Jin H, Gulhan DC, Geiger B, Ben-Isvy D, Geng D, Ljungström V, Park PJ.
Nat Genet
View full abstract on Pubmed
Chromosome evolution screens recapitulate tissue-specific tumor aneuploidy patterns.
Authors: Watson EV, Lee JJ, Gulhan DC, Melloni GEM, Venev SV, Magesh RY, Frederick A, Chiba K, Wooten EC, Naxerova K, Dekker J, Park PJ, Elledge SJ.
Nat Genet
View full abstract on Pubmed
Comparative Evaluation of Proton Therapy and Volumetric Modulated Arc Therapy for Brachial Plexus Sparing in the Comprehensive Reirradiation of High-Risk Recurrent Breast Cancer.
Authors: Choi JI, McCormick B, Park P, Millar M, Walker K, Tung CC, Huang S, Florio P, Chen CC, Lozano A, Hanlon AL, Fox J, Xu AJ, Zinovoy M, Mueller B, Bakst R, LaPlant Q, Braunstein LZ, Khan AJ, Powell SN, Cahlon O.
Adv Radiat Oncol
View full abstract on Pubmed
Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signatures.
Authors: Gulhan DC, Viswanadham V, Muyas F, Jin H, Foote MB, Lee JJ, Barras D, Jung YL, Ljungstrom V, Rousseau B, Galor A, Diplas BH, Maron SB, Cleary JM, Cortés-Ciriano I, Park PJ.
medRxiv
View full abstract on Pubmed
A role for mutations in AK9 and other genes affecting ependymal cells in idiopathic normal pressure hydrocephalus.
Authors: Yang HW, Lee S, Berry BC, Yang D, Zheng S, Carroll RS, Park PJ, Johnson MD.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma.
Authors: Marino-Enriquez A, Novotny JP, Gulhan DC, Klooster I, Tran AV, Kasbo M, Lundberg MZ, Ou WB, Tao DL, Pilco-Janeta DF, Mao VY, Zenke FT, Leeper BA, Gokhale PC, Cowley GS, Baker LH, Ballman KV, Root DE, Albers J, Park PJ, George S, Fletcher JA.
Clin Cancer Res
View full abstract on Pubmed